Sacubitril sodium

Modify Date: 2024-01-08 12:42:34

Sacubitril sodium structure	Common Name	Sacubitril sodium
	CAS Number	149690-05-1	Molecular Weight	433.47300
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₄H₂₈NNaO₅	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Sacubitril sodium

Sacubitril sodium is a potent and orally active NEP (neprilysin) inhibitor, with an IC50 of 5 nM. Sacubitril sodium enhances the tone of the natriuretic peptide (NP) system and exerts significant antihypertensive effects. Sacubitril sodium is a component of the heart failure medicine LCZ696. Sacubitril sodium can be used for the research of heart failure, hypertension and COVID-19[1][2][3].

Name	sodium,4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate
Synonym	More Synonyms

Description	Sacubitril sodium is a potent and orally active NEP (neprilysin) inhibitor, with an IC50 of 5 nM. Sacubitril sodium enhances the tone of the natriuretic peptide (NP) system and exerts significant antihypertensive effects. Sacubitril sodium is a component of the heart failure medicine LCZ696. Sacubitril sodium can be used for the research of heart failure, hypertension and COVID-19[1][2][3].
Related Catalog	Research Areas >> Cardiovascular Disease Research Areas >> Infection Signaling Pathways >> Metabolic Enzyme/Protease >> Neprilysin
In Vitro	Sacubitril sodium increases neprylisin-degraded peptides, such as natriuretic peptides (NPs), peptide natriuretic atrial (ANP) and peptide natriuretic brain (BNP)[2].
In Vivo	In normotensive rats, pretreatment with Sacubitril sodium (3, 10 and 30 mg/kg, PO.) augments ANP-evoked plasma cGMP levels by 2.4, 3.3 and 4.0 fold, respectively (4h AUC compared to vehicle)[1]. Sacubitril sodium (30 and 100 mg/kg, PO) produces a dose-dependent antihypertensive effect in Dahl-SS rats[1].
References	[1]. Hegde, L.G., et al. Comparative efficacy of AHU-377, a potent neprilysin inhibitor, in two rat models of volume-dependent hypertension. BMC Pharmacol 11, P33 (2011). [2]. Vitiello A, et al. Sacubitril, valsartan and SARS-CoV-2. BMJ Evid Based Med. 2020 Jul 27:bmjebm-2020-111497. [3]. Chrysant SG. Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan. J Am Soc Hypertens. 2017 Jul;11(7):461-468.